Authors: Namer, M Soler-Michel, P Turpin, F Chinet-Charrot, P de Gislain, C Pouillart, P Delozier, T Luporsi, E Etienne, PL Schraub, S Eymard, JC Serin, D Ganem, G Calais, G Maillart, P Colin, P Trillet-Lenoir, V Prevost, G Tigaud, D Clavere, P Marti, P Romieu, C Wendling, JL

Citation: M. Namer et al., Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer, EUR J CANC, 37(9), 2001, pp. 1132-1140

Authors: Adenis, A Bonneterre, J Bonneterre, ME Pion, JM Vanlemmens, L Gladieff, L de Lafontan, B Martel, P Mihura, J Roche, H Gedouin, D Kerbrat, P Lesimple, T Bremond, A Devaux, Y Delecroix, V Fumoleau, P Maugard-Louboutin, C Namer, M Goudier, MJ Morice, F Montcuquet, P Schraub, S Coudert, B Fargeot, P de Gislain, C Mayer, F Bastit, P Chevallier, B Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Datchary, J Audhuy, B Barats, JC Kohser, F Dides, S Ramos, R Cattan, A Eymard, JC Pourny, C Weber, B de Laroche, G Pichon, A Seffert, P Hayat, M Zambon, E Chollet, P Van Praagh, I

Citation: A. Adenis et al., Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial, J CL ONCOL, 19(3), 2001, pp. 602-611

Authors: Tubiana-Mathieu, N Lejeune, C Bonnier, P Genet, D Adjadj, DJ Berdah, JF Muracciole, X Delaby, F Clavere, P Benyoub, A Roullet, B Rhein, B Juin, P Piana, L

Citation: N. Tubiana-mathieu et al., Chemotherapy and concomitant irradiation in inflammatory breast cancer, ANTICANC R, 21(4B), 2001, pp. 3061-3067

Authors: Bonnafoux-Clavere, A Clavere, P Bonnetblanc, JM

Citation: A. Bonnafoux-clavere et al., Radiation induced skin reaction, ANN DER VEN, 128(8-9), 2001, pp. 947-950

Authors: Leguene, C Clavere, P Jore, D Gardes-Albert, M

Citation: C. Leguene et al., Radiolytic oxidation of tamoxifen using the free radicals OH and (or) HO2, CAN J PHYSL, 79(2), 2001, pp. 184-188

Authors: Bastit, P Chevallier, B Chevreau, C Mihura, J Roche, H Namer, M Gedouin, D Kerbrat, P Lesimple, T Coudert, B Fargeot, P de Gislain, C Mayer, F Luporsi, E Rios, M Weber, B Bremond, A Devaux, Y Monteuquet, P Schraub, S Hayat, M Zambon, E Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Chollet, P Van Praagh, I Cattan, A Eymard, JC Pourny, C Facchini, T Walter, S Dides, S Ramos, R Guiochet, N Seffert, P Perpoint, X Sztermer, JF Cretin, J Goudier, MJ Morice, F Delecroix, V Fumoleau, P

Citation: P. Bastit et al., Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment, J CL ONCOL, 18(17), 2000, pp. 3115-3124